QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

Help viewing high resolution images Return to article

Fig. 1. Gene-Switch system drives targeted dFMRP expression in neurons. (A) Schematic of the Gene-Switch (GS) system. The GAL4 DNA-binding domain is fused to the p65 activation domain (p65AD) and a mutated progesterone receptor ligand-binding domain (PR-LBD). In the absence of RU486, the GS is `off'. In the presence of RU486, the hormone-responsive GAL4 drives dFMRP transcription downstream of the UAS regulatory sequence. This approach allows spatial and temporal control of dFMRP expression in the dfmr1-null background. (B) Western blot of isolated third instar Drosophila larval CNS. Genotypes as indicated: w¹¹¹⁸ (control), homozygous dfmr1^50M null allele (dfmr1) and dfmr1^50M, elav-GSG-301/dfmr1^50M, UAS-9557-3 (GS). Treatment as indicated: GS fed ethanol vehicle (GS+E) or RU486 (GS+RX, where X is the RU486 concentration in µg/mL). Blot was probed for dFMRP and -Tubulin, illustrating RU486 dosage responsiveness. (C) Quantification of western blot dFMRP levels. Individual band intensities were normalized to -Tubulin and expressed as a percentage of the control. Bars indicate mean±s.e.m. ^*P<0.05. (D) dFMRP immunohistochemistry of wandering third instar larvae CNS. Bottom row of panels shows higher magnification views of dFMRP staining in the VNC. Note the RU486 dosage dependence of dFMRP expression.

Return to article